A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
J2W-MC-PYAA - ClinicalTrials.gov - NCT04411628
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it.
Trial Summary
Age Range
18 - 75 yearsConditions the trial is for
COVID-19What the trial is testing?
BamlanivimabCould I receive a Placebo?
YesEnrollment Goal
26Trial Dates
May 28, 2020 - Aug 26, 2020How long will I be in the trial?
Participation could last about 8 weeks and may include up to 15 visits in the hospital or in the home.Trial Phase
ILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo